Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 617-707-0 | CAS number: 85390-93-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Justification for classification or non-classification
There are no data available on 3 beta,7 beta,15 alpha-Trihydroxy-5-androsten-17-one or the stereoisomer 3 beta,7 alpha,15 alpha-Trihydroxy-5-androsten-17-one.
Since 3 beta,7 beta,15 alpha-Trihydroxy-5-androsten-17-one is a derivative of the steroid hormone prasteron with a high structural similarity similar effects can be expected. Prasteron was shown in animal experiments to have the ability to inhibit fertility in rodents in high doses. Such disturbances to sexual function should fundamentally also be taken into consideration following intake of 3 beta,7 beta,15 alpha-Trihydroxy-5-androsten-17-one. Moreover, reproduction toxicity data in rats indicate that prasteron has a virilizing potential in female fetuses. This finding is explicable either by the moderate androgenic activity of prasteron itself or by the metabolism of the compound to endogenous androgens such as testosterone or dihydrotestosterone. As a matter of precaution, the risk of a virilizing effect in female offspring should also be assumed if women are burdened with 3 beta,7 beta,15 alpha-Trihydroxy-5-androsten-17-one during the sensitive phase of fetal sexual differentiation. Animal experiments produced no indication that prasteron may possess a teratogenic potential beyond this. In analogy to prasteron, exposure of nursing women is fundamentally to be avoided as neither the entry of 3 beta,7 beta,15 alpha-Trihydroxy-5-androsten-17-one and/or possible metabolites into the mother's milk nor an inhibition of the milk production can yet be excluded. A potential risk to the development of the infant has thus to be assumed.
According to the Directive 67/548/EEC, 3 beta,7 beta,15 alpha-Trihydroxy-5-androsten-17-one is classified:
Repr. Category 2; R60 - May impair fertility.
Repr. Category 2; R61 - Possible risk of harm to the unborn child.
R64 - May cause harm to breast-fed babies.
According to Regulation (EC) 1272/2008 (CLP) 3 beta,7 beta,15 alpha-Trihydroxy-5-androsten-17-one is classified:
Repr. Category 1B; H360 FD
Lact.; H362 .
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.